Mumbai's ENTOD Pharma Secures Patent for Insulin Eye Drops in Pre-clinical Trials
Source: ET Real Estate
Arth Insight · What this means for your wallet
- This is a very early-stage development (pre-clinical trials); it will not affect your current medical expenses or insurance premiums for eye care anytime soon.
- If successful and approved in several years, this could offer a new treatment for certain eye conditions, potentially improving care or offering an alternative to existing therapies.
- The news signals domestic innovation in healthcare, which in the long run could contribute to more accessible and tailored medical solutions within India.
Mumbai-based ENTOD Pharmaceuticals has secured a patent for its innovative insulin eye drop, currently in the pre-clinical stage of development. This novel therapeutic approach is being investigated to address unmet needs in ophthalmic care, marking a significant step in medical research.
- ▸Mumbai-based ENTOD Pharmaceuticals has secured a patent for an insulin eye drop.
- ▸The patented eye drop is currently in the pre-clinical stage of development.
- ▸It aims to explore a novel therapeutic approach for unmet needs in eye care.
- ▸This represents a key step in medical innovation by an Indian pharmaceutical company.
- ✓Mumbai-based ENTOD Pharmaceuticals has secured a patent for an insulin eye drop.
- ✓The patented eye drop is currently in the pre-clinical stage of development.
- ✓It aims to explore a novel therapeutic approach for unmet needs in eye care.
- ✓This represents a key step in medical innovation by an Indian pharmaceutical company.
ENTOD Pharmaceuticals, a Mumbai-based pharmaceutical company, has announced that it has successfully secured a patent for its novel insulin eye drop formulation. This development positions the company at the forefront of exploring new therapeutic avenues in ophthalmic care.
The patented insulin eye drops are currently in the pre-clinical stage of development. This early phase involves extensive laboratory testing and studies to evaluate the safety, dosage, and initial efficacy of the new drug before it can be considered for human clinical trials. The company stated that these eye drops are being investigated as a potential new therapeutic approach specifically designed to address unmet needs within the broader spectrum of ophthalmic conditions.
Significance of the Patent
Securing a patent is a crucial milestone for any pharmaceutical company. It grants ENTOD Pharmaceuticals exclusive rights to their innovative insulin eye drop for a specified period, protecting their intellectual property and research investment. This exclusivity is vital in the highly competitive pharmaceutical industry, allowing companies to recoup their development costs and fund further research into new treatments.
For the healthcare sector, particularly in India, the development signifies a push towards home-grown innovation in critical medical areas. Ophthalmic care is a field with a constant demand for advanced treatments, given the rising prevalence of various eye conditions, including those linked to lifestyle diseases. While the exact conditions targeted by ENTOD's insulin eye drop have not been specified beyond 'unmet needs in ophthalmic care,' the use of insulin suggests a potentially novel mechanism of action that could benefit a range of patients.
The Path Ahead for Insulin Eye Drops
As the insulin eye drops are still in the pre-clinical stage, there is a significant journey ahead before they can potentially reach patients. This path includes rigorous human clinical trials (Phases 1, 2, and 3), regulatory approvals from bodies like the Central Drugs Standard Control Organization (CDSCO) in India, and eventually, manufacturing and commercialization. Each stage is designed to ensure the safety and effectiveness of the drug for public use.
The announcement underscores the ongoing efforts by Indian pharmaceutical companies to contribute to global medical innovation. For Indian retail readers, such developments highlight advancements in domestic healthcare research that could, in the long term, lead to more accessible or effective treatment options for various health conditions, particularly those affecting the eyes.
This report is for informational purposes only and does not constitute medical or investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Which company recently secured a patent for an insulin eye drop?
Mumbai-based ENTOD Pharmaceuticals has secured the patent.
What stage of development is the patented insulin eye drop currently in?
The insulin eye drop is currently in the pre-clinical stage of development.
What is the purpose of this patented eye drop?
It is being investigated as a potential novel therapeutic approach to address unmet needs in ophthalmic care.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Related Stories
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.